Objective: Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.
Methods: A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.
Results: Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.
Conclusion: The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.181054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-designing a low-intensity psychological therapy for fear of recurrence in psychosis using translational learning from fear of recurrence in oncology: protocol for intervention development for future testing in a feasibility study.
BMJ Open
December 2024
School of Health & Wellbeing, University of Glasgow, Glasgow, UK.
Introduction: Fear of recurrence is a transdiagnostic problem experienced by people with psychosis, which is associated with anxiety, depression and risk of future relapse events. Despite this, there is a lack of available psychological interventions for fear of recurrence, and psychological therapies for schizophrenia are often poorly implemented in general. However, low-intensity psychological therapy is available for people who experience fear of recurrence in the context of cancer, which means there is an opportunity to learn what has worked in a well-implemented psychological therapy to see if any learning can be adapted for schizophrenia care.
View Article and Find Full Text PDFConceptualizing patient-level adverse effects in implementation trials.
Ann Epidemiol
December 2024
Department of Internal Medicine, University of Botswana, Gaborone, Botswana.
Identifying and monitoring adverse effects (AEs) are integral to ensuring patient safety in clinical trials. Research sponsors and regulatory bodies have put into place a variety of policies and procedures to guide researchers in protecting patient safety during clinical trials. However, it remains unclear how these policies and procedures should be adapted for trials in implementation science.
View Article and Find Full Text PDFClinical evaluation of single bond universal adhesive in non-carious cervical lesions: a 36-month retrospective study.
Clin Oral Investig
December 2024
Faculty of Dentistry, Department of Restorative Dentistry, Eskisehir Osmangazi University, Eskisehir, Turkey.
Objective: To evaluate the 36-month clinical performance of Single Bond Universal Adhesive (SBU; 3M ESPE, Germany) in non-carious cervical lesions (NCCLs) using different modes of adhesion according to the FDI criteria. The primary outcome was the retention loss of the restorations, while the secondary outcomes included marginal staining, marginal adaptation, post-operative sensitivity and tooth vitality, recurrence of caries erosion and abfraction, and tooth integrity, all evaluated according to the FDI criteria.
Materials And Methods: In this study, the SBU Adhesive was applied to 246 NCCLs of 25 patients using different modes of adhesion: Self-etch (SE), selective-enamel-etching (SLE), and etch-and-rinse (ER).
POP-REFINE: A Comprehensive Framework for Evaluating and Optimizing Representativeness in Clinical Trials.
Clin Pharmacol Ther
December 2024
Flatiron Health, New York, NY, USA.
Clinical research has historically failed to include representative levels of historically underrepresented populations and these inequities continue to persist. Ensuring representativeness in clinical trials is crucial for patients to receive clinically appropriate treatment and have equitable access to novel therapies; enhancing the generalizability of study results; and reducing the need for post-marketing commitments focused on underrepresented groups. As demonstrated by recent legislation and guidance documents, regulatory agencies have shown an increased interest in understanding how novel therapies will impact the patient population that will receive them.
View Article and Find Full Text PDFIntervention description of pharmacist-facilitated medication reviews in Nordic primary care settings: a scoping review.
Scand J Prim Health Care
December 2024
Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Background: Multicomponent interventions are increasingly utilized to tackle the complexity of aging and co-morbid patients. However, descriptions of interventions are generally poor, making it difficult for healthcare providers to implement successful programs.
Objectives: This study aimed to explore the completeness of intervention description of pharmacist-facilitated medication reviews (MRs) in Nordic primary care settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!